Histopathology of BRCA1- and BRCA2-associated breast cancer

被引:62
作者
Honrado, Emiliano
Benitez, Javier
Palacios, Jose
机构
[1] Ctr Nacl Invest Oncol, Breast & Gynaecol Canc Grp, E-28029 Madrid, Spain
[2] Ctr Nacl Invest Oncol, Dept Human Genet, E-28029 Madrid, Spain
关键词
hereditary breast cancer; BRCA1; BRCA2; molecular pathology; histopathology; immunohistochemistry;
D O I
10.1016/j.critrevonc.2006.01.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hereditary breast carcinomas that are attributable to BRCA1/2 mutations have their own morphological and immunohistochemical characteristics. BRCA1-associated carcinomas are poorly differentiated infiltrating ductal carcinomas that frequently show morphological features of typical or atypical medullary carcinoma. BRCA2-associated breast carcinomas tend to be of higher grade than sporadic age-matched controls. BRCA1 tumors have been found to be more frequently estrogen receptor- and progesterone receptor-negative, and p53-positive than are age-matched controls, whereas these differences are not usually found in BRCA2-associated tumors. In addition, BRCA1- and BRCA2-associated breast carcinomas show a low frequency of HER2 expression. Most BRCA1 breast carcinomas are characterized by the expression of basal (myoepithelial) markers, such as cytokeratin 5/6 and or P-cadherin. These features could be used to distinguish patients who are likely to carry a BRCA1 or BRCA2 germline mutation, thus indicating which gene should be screened for first in families with a high incidence of breast and ovarian cancer. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:27 / 39
页数:13
相关论文
共 124 条
[11]   Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer [J].
Cavalli, LR ;
Singh, B ;
Isaacs, C ;
Dickson, RB ;
Haddad, BR .
CANCER GENETICS AND CYTOGENETICS, 2004, 149 (01) :38-43
[12]  
Chappuis PO, 2000, SEMIN SURG ONCOL, V18, P287, DOI 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.3.CO
[13]  
2-X
[14]   Cyclin E expression in breast cancer:: predicting germline BRCA1 mutations, prognosis and response to treatment [J].
Chappuis, PO ;
Donato, E ;
Goffin, JR ;
Wong, N ;
Bégin, LR ;
Kapusta, LR ;
Brunet, JS ;
Porter, P ;
Foulkes, WD .
ANNALS OF ONCOLOGY, 2005, 16 (05) :735-742
[15]   Germline BRCA1/2 mutations and p27Kip1 protein levels independently predict outcome after breast cancer [J].
Chappuis, PO ;
Kapusta, L ;
Bégin, LR ;
Wong, N ;
Brunet, JS ;
Narod, SA ;
Slingerland, J ;
Foulkes, WD .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) :4045-4052
[16]   Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ [J].
Claus, EB ;
Petruzella, S ;
Matloff, E ;
Carter, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (08) :964-969
[17]   Extensive experience of disease control with gefitinib and the role of prognostic markers [J].
Cortes-Funes, H ;
Soto Parra, H .
BRITISH JOURNAL OF CANCER, 2003, 89 (Suppl 2) :S3-S8
[18]   p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours [J].
Crook, T ;
Brooks, LA ;
Crossland, S ;
Osin, P ;
Barker, KT ;
Waller, J ;
Philp, E ;
Smith, PD ;
Yulug, I ;
Peto, J ;
Parker, G ;
Allday, MJ ;
Crompton, MR ;
Gusterson, BA .
ONCOGENE, 1998, 17 (13) :1681-1689
[19]   The Fanconi anaemia BRCA pathway [J].
D'Andrea, AD ;
Grompe, M .
NATURE REVIEWS CANCER, 2003, 3 (01) :23-34
[20]   Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients:: A high proportion of mutations unique to Spain and evidence of founder effects [J].
Díez, O ;
Osorio, A ;
Durán, M ;
Martinez-Ferrandis, JI ;
de la Hoya, M ;
Salazar, R ;
Vega, A ;
Campos, B ;
Rodríguez-López, R ;
Velasco, E ;
Chaves, J ;
Díaz-Rubio, E ;
Cruz, JJ ;
Torres, M ;
Esteban, E ;
Cervantes, A ;
Alonso, C ;
San Román, JM ;
González-Sarmiento, R ;
Miner, C ;
Carracedo, A ;
Armengod, ME ;
Caldés, T ;
Benítez, J ;
Baiget, M .
HUMAN MUTATION, 2003, 22 (04) :301-312